Targeting alpha 5 beta 1 integrin as a therapeutic strategy to combat right ventricular dysfunction in pulmonary arterial hypertension
Sarah‐Eve Lemay(SNC-Lavalin (Canada)), S Bonnet(Institut universitaire de cardiologie et de pneumologie de Québec), Steeve Provencher(Institut universitaire de cardiologie et de pneumologie de Québec), Mélanie Sauvaget(Canadian Heart Research Centre), Olivier Boucherat, Manon Mougin(Canadian Heart Research Centre), Charlie Théberge(Canadian Heart Research Centre), R. Desbiens(Lung Institute), Andréanne Pelletier(Canadian Heart Research Centre), Alice Bourgeois, F Potus(Institut universitaire de cardiologie et de pneumologie de Québec), Yann Grobs(Institut universitaire de cardiologie et de pneumologie de Québec), S Breuils-Bonnet(Institut universitaire de cardiologie et de pneumologie de Québec), Sandra Martineau(Canadian Heart Research Centre)
Cited by 0
Related Papers
Defining the clinical validity of genes reported to cause pulmonary arterial hypertension
|Genetics in Medicine|2023|73
Oxidized DNA Precursors Cleanup by NUDT1 Contributes to Vascular Remodeling in Pulmonary Arterial Hypertension
|American Journal of Respiratory and Critical Care Medicine|2020|34
ATP citrate lyase drives vascular remodeling in systemic and pulmonary vascular diseases through metabolic and epigenetic changes
|Science Translational Medicine|2024|33